James E. Herndon
- Genetics top 0.01%
- Glioma Diagnosis and Treatment 150
- Oncology top 0.05%
- Lung Cancer Research Studies 72
- Cancer survivorship and care 35
- Pulmonary and Respiratory Medicine top 0.02%
- Lung Cancer Treatments and Mutations 95
- Lung Cancer Diagnosis and Treatment 77
- Brain Metastases and Treatment 63
- Cancer Research top 0.1%
- Cancer, Hypoxia, and Metabolism 26
-
- Immunotherapy and Immune Responses 29
- Co-authors
- Henry S. FriedmanAllan H. FriedmanDarell D. BignerDavid A. ReardonRoger E. McLendonJohn H. SampsonMark R. GreenJames J. Vredenburgh
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
James E. Herndon
461 papers receiving 36.6k citations
Hit Papers
Peers
Comparison fields: 5 of 182
- Genetics 11.5k
- Oncology 13.5k
- Pulmonary and Respiratory Medicine 15.2k
- Cancer Research 5.8k
- Radiology, Nuclear Medicine and Imaging 5.1k
Countries citing papers authored by James E. Herndon
This map shows the geographic impact of James E. Herndon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Herndon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Herndon more than expected).
Fields of papers citing papers by James E. Herndon
This network shows the impact of papers produced by James E. Herndon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Herndon. The network helps show where James E. Herndon may publish in the future.
Co-authorship network
The 25 scholars most cited alongside James E. Herndon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 7 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 0 | |
| 4 | 2023 | 7 | |
| 5 | 2021 | 3 | |
| 6 | 2021 | 15 | |
| 7 | 2019 | 5 | |
| 8 | 2019 | 11 | |
| 9 | 2018 | 38 | |
| 10 | 2017 | 242 | |
| 11 | 2014 | 57 | |
| 12 | 2013 | 241 | |
| 13 | 2013 | 156 | |
| 14 | 2011 | 94 | |
| 15 | 2011 | 112 | |
| 16 | Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastomabreakdown → | 2010 | 613 |
| 17 | 2009 | 221 | |
| 18 | 2008 | 130 | |
| 19 | Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groupsbreakdown → | 2008 | 690 |
| 20 | 2007 | 193 |
About James E. Herndon
James E. Herndon is a scholar working on Genetics, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 482 papers that have together received 37.5k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (150 papers), Lung Cancer Treatments and Mutations (95 papers), Lung Cancer Diagnosis and Treatment (77 papers), Lung Cancer Research Studies (72 papers), Brain Metastases and Treatment (63 papers), Cancer survivorship and care (35 papers), Immunotherapy and Immune Responses (29 papers) and Cancer, Hypoxia, and Metabolism (26 papers). The work is most often cited by research in Genetics (11.5k citations), Oncology (13.5k citations), Pulmonary and Respiratory Medicine (15.2k citations), Cancer Research (5.8k citations) and Radiology, Nuclear Medicine and Imaging (5.1k citations). James E. Herndon has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Henry S. Friedman, Allan H. Friedman, Darell D. Bigner, David A. Reardon, Roger E. McLendon, John H. Sampson, Mark R. Green, James J. Vredenburgh, Annick Desjardins and Edward F. Patz. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Neuro-Oncology, Lung Cancer and Journal of Neuro-Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.